0001628280-21-012169.txt : 20210614 0001628280-21-012169.hdr.sgml : 20210614 20210614161039 ACCESSION NUMBER: 0001628280-21-012169 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210610 FILED AS OF DATE: 20210614 DATE AS OF CHANGE: 20210614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ADAMS THOMAS PHD CENTRAL INDEX KEY: 0001234366 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35558 FILM NUMBER: 211014717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cardiff Oncology, Inc. CENTRAL INDEX KEY: 0001213037 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 272004382 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-952-7570 MAIL ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Trovagene, Inc. DATE OF NAME CHANGE: 20130304 FORMER COMPANY: FORMER CONFORMED NAME: TrovaGene Inc. DATE OF NAME CHANGE: 20110830 FORMER COMPANY: FORMER CONFORMED NAME: XENOMICS INC DATE OF NAME CHANGE: 20040719 4 1 wf-form4_162370142446711.xml FORM 4 X0306 4 2021-06-10 0 0001213037 Cardiff Oncology, Inc. CRDF 0001234366 ADAMS THOMAS PHD C/O CARDIFF ONCOLOGY, INC. 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 0 0 0 1 Former Director Stock Options 447.84 2021-06-10 4 J 0 272 0 A 2023-06-10 Common Stock 272.0 477870 D Stock Options 7.18 2021-06-10 4 J 0 223 0 A 2016-03-17 2023-06-10 Common Stock 223.0 477870 D Stock Options 5.18 2021-06-10 4 J 0 223 0 A 2017-01-04 2023-06-10 Common Stock 223.0 477870 D Stock Options 51.84 2021-06-10 4 J 0 530 0 A 2018-10-04 2023-06-10 Common Stock 530.0 477870 D Stock Options 21.6 2021-06-10 4 J 0 755 0 A 2019-01-23 2023-06-10 Common Stock 755.0 477870 D Stock Options 2.48 2021-06-10 4 J 0 298320 0 A 2020-12-29 2023-06-10 Common Stock 298320.0 477870 D Stock Options 2.6 2021-06-10 4 J 0 173145 0 A 2020-12-29 2023-06-10 Common Stock 173145.0 477870 D Expiration date of the stock options was extended to June 10, 2023. 7,338 of the stock options vest immediately. 4,077 of the stock options vest on each of 2/25/2015 and 2016 and 4,076 of the stock options vest on 2/25/2017. In connection with the Reporting Person's separation agreement dated December 21, 2020, the Compensation Committee accelerated the vesting of such stock options to December 29, 2020. /s/ Thomas Adams 2021-06-14